Biogenerics in the U.S. will happen — it’s just a matter of when, according to Teva Pharmaceuticals’ head of North America.
George Barrett told the Reuters Health Summit that while next year is a toss-up given it’s an election year, setting up the regulatory pathway for biogeneirics to get to market is critical in the next two years ahead of wave of patents due to expire in five years.
Barrett was one of the featured speakers in the final day of the annual Reuters Health Summit speaking from our New York headquarters.
